We are pleased to share that our latest paper has been accepted for publication in the Computational and Structural Biotechnology Journal (CSBJ). The paper, titled “CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy: Collaborative Translation of Scientific Discoveries into Advanced Treatments for Neurological Rare Genetic Diseases and Cancer” provides an in-depth look at our ongoing efforts to advance gene and cell therapy technologies.
About the Paper
The paper outlines the establishment and goals of the Centre of Excellence for the Technologies of Gene and Cell Therapy (CTGCT) at the National Institute of Chemistry (NIC) in Ljubljana, Slovenia. The CTGCT is a collaborative effort involving partner institutions from the UK, the Netherlands, and Germany, including University College London, University Medical Center Utrecht, Charité University Hospital Berlin, and Technical University Dresden.
Key Focus Areas
Cancer Immunotherapy
The CTGCT is developing advanced CAR T-cell technology, CRISPR/Cas mediated gene editing, and RNA splicing technologies to target hematologic cancers and address the challenges associated with solid tumors.
Rare Genetic Diseases
Our research focuses on rare genetic diseases such as CTNNB1 syndrome, Kleefstra syndrome, and SATB2-associated syndrome. We aim to develop personalized therapies using technologies like next-generation sequencing and synthetic biology.
Translational Research
The CTGCT’s Translational Research Unit and Technology Transfer Office will facilitate the dissemination of research results and innovations. Our newly established GMP facilities will support the translation of gene and cell therapies from research to clinical practice.
Access the Paper
You can access the full paper in this link. We encourage you to read and share it with your colleagues and peers.